{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:17:57Z","timestamp":1773238677033,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T00:00:00Z","timestamp":1552348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1007\/s40290-019-00267-2","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T12:00:51Z","timestamp":1552392051000},"page":"145-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0448-7111","authenticated-orcid":false,"given":"Comfort Kunak","family":"Ogar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiodun","family":"Abiola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Yuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Adekunle","family":"Oreagba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel C.","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojisola Christianah","family":"Adeyeye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazeem Adeola","family":"Oshikoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,12]]},"reference":[{"key":"267_CR1","volume-title":"The importance of pharmacovigilance. Safety monitoring of medicinal products","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The importance of pharmacovigilance. Safety monitoring of medicinal products. Geneva: World Health Organization; 2002."},{"issue":"9237","key":"267_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"key":"267_CR3","unstructured":"International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline post-approval safety data management: definitions and standards for expedited reporting E2D. Current Step 4 version dated 12 November 2003. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2D\/Step4\/E2D_Guideline.pdf. Accessed 10 Dec 2018."},{"issue":"5","key":"267_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"key":"267_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2167-0870.1000155","volume":"4","author":"M Kharkar","year":"2014","unstructured":"Kharkar M, Bowalekar S. Extent of under reporting of adverse drug reactions (ADRs) in India: evaluation using logistic regression analysis (LRA) model. J Clin Trials. 2014;4:1. https:\/\/doi.org\/10.4172\/2167-0870.1000155.","journal-title":"J Clin Trials"},{"issue":"1","key":"267_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/0253-7613.150344","volume":"47","author":"VR Tandon","year":"2015","unstructured":"Tandon VR, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India. Indian J Pharmacol. 2015;47(1):65\u201371.","journal-title":"Indian J Pharmacol"},{"key":"267_CR7","unstructured":"la Santos A. Direct Patient reporting in the European Union: a snapshot of reporting systems in seven member states. Amsterdam: Health Action International; 2015. http:\/\/apps.who.int\/medicinedocs\/documents\/s22088en\/s22088en.pdf. Accessed 8 Dec 2018."},{"key":"267_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1472-6904-9-14","volume":"9","author":"KA Oshikoya","year":"2009","unstructured":"Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos Nigeria. BMC Clin Pharmacol. 2009;9:14.","journal-title":"BMC Clin Pharmacol"},{"key":"267_CR9","unstructured":"National Bureau of Statistics. Demographic Statistics Bulletin; 2017. https:\/\/nigerianstat.gov.ng\/download\/775. Accessed 6 Dec 2018."},{"key":"267_CR10","first-page":"53","volume":"51","author":"A Scott-Emuakpor","year":"2010","unstructured":"Scott-Emuakpor A. The evolution of health care systems in Nigeria: which way forward in the twenty-first century. Niger Med J. 2010;51:53\u201365.","journal-title":"Niger Med J"},{"key":"267_CR11","unstructured":"Federal Ministry of Health, Nigeria. National Drug Policy, 2005. ISBN 978-067-237-0."},{"key":"267_CR12","unstructured":"National Agency for Food and Drug Administration and Control NAFDAC Act 2004. http:\/\/www.nafdac.gov.ng\/index.php\/about-nafdac\/nafdac-act. Accessed 3 Aug 2016."},{"key":"267_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40290-018-0228-8","volume":"32","author":"CK Ogar","year":"2018","unstructured":"Ogar CK, Ibrahim A, Osakwe AI, Jajere F, Kigbu-Adekunle AA, Alonge K, et al. Pharmacovigilance Rapid Alert System for Consumer Reporting (PRASCOR): a look at its quantitative contribution to spontaneous reporting in Nigeria from August 2012 to February 2017. Pharm Med. 2018;32:131. https:\/\/doi.org\/10.1007\/s40290-018-0228-8.","journal-title":"Pharm Med"},{"issue":"2","key":"267_CR14","doi-asserted-by":"publisher","first-page":"e00297","DOI":"10.1002\/prp2.297","volume":"5","author":"IA Oreagba","year":"2017","unstructured":"Oreagba IA, Oshikoya KA, Ogar C, Adefurin AO, Ibrahim A, Awodele O, Oni Y. Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016. Pharmacol Res Perspect. 2017;5(2):e00297.","journal-title":"Pharmacol Res Perspect"},{"key":"267_CR15","first-page":"1","volume":"2","author":"KA Oshikoya","year":"2010","unstructured":"Oshikoya KA. Treating children for malaria fever in the face of counterfeit and fake medicines. Int J Med Med Sci. 2010;2:1\u20132.","journal-title":"Int J Med Med Sci"},{"key":"267_CR16","first-page":"403","volume":"34","author":"FA Fehintola","year":"2005","unstructured":"Fehintola FA. Dipyrone: the ban, the justification. Afr J Med Med Sci. 2005;34:403\u20134.","journal-title":"Afr J Med Med Sci"},{"key":"267_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JRS-160669","volume":"28","author":"O Awodele","year":"2016","unstructured":"Awodele O, Ibrahim A, Orhii P. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November 2014. Int J Risk Saf Med. 2016;28:13\u201323. https:\/\/doi.org\/10.3233\/JRS-160669.","journal-title":"Int J Risk Saf Med"},{"key":"267_CR18","unstructured":"The use of the WHO-UMC system for standardized case causality assessment. https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf. Accessed 14 Feb 2019."},{"key":"267_CR19","unstructured":"Uppsala Monitoring Centre. Safety monitoring of medicinal products: guidelines for setting up and running a pharmacovigilance centre. UMC, WHO Collaborating Centre for International Drug Monitoring, Sweden; 2000."},{"issue":"6","key":"267_CR20","first-page":"413","volume":"32","author":"R Kiguba","year":"2018","unstructured":"Kiguba R, Ndagije HB, Nambasa V, Bird SM. Adverse Drug Reaction Onsets in Uganda\u2019s VigiBase\u00ae: delayed international visibility, data quality and illustrative signal detection analyses. Pharmaceut Med. 2018;32(6):413\u201327.","journal-title":"Pharmaceut Med"},{"key":"267_CR21","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA. 1998;279:1200\u20135.","journal-title":"JAMA"},{"issue":"12","key":"267_CR22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/BF03262002","volume":"35","author":"L Aagaard","year":"2012","unstructured":"Aagaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase. Drug Saf. 2012;35(12):1171\u201382.","journal-title":"Drug Saf"},{"issue":"2","key":"267_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2125.2007.02993.x","volume":"65","author":"R Arulmani","year":"2008","unstructured":"Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in south India. Br J Clin Pharmacol. 2008;65(2):210\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 3","key":"267_CR24","first-page":"98","volume":"5","author":"R Kamalraj","year":"2012","unstructured":"Kamalraj R, Revathy J, Vijey Aanandhi M, Murugan M, Ramamakumar KPV. Incidence, severity and financial burden associated with suspected unexpected serious adverse reactions (SUSARS) that arise in clinical trials. Asian J Phar Clin Res. 2012;5(Suppl 3):98\u2013101.","journal-title":"Asian J Phar Clin Res"},{"issue":"3","key":"267_CR25","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.phrs.2006.05.003","volume":"54","author":"J Jose","year":"2006","unstructured":"Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res. 2006;54(3):226\u201333.","journal-title":"Pharmacol Res"},{"issue":"1","key":"267_CR26","first-page":"30","volume":"24","author":"KA Agu","year":"2014","unstructured":"Agu KA, Isah MA, Oqua D, Habeeb MA, Agada PO, Ohiaeri SI, Ali PN, Iyaji PG, King RC, Aiyenigba B, Torpey K, Chabikuli ON, Wutoh AK. Incidence of adverse drug reactions in patients on antiretroviral therapy: a study of pharmaceutical care in HIV interventions in Nigeria. West Afr J Pharm. 2014;24(1):30\u201342.","journal-title":"West Afr J Pharm"},{"issue":"2","key":"267_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/2229-3485.111784","volume":"4","author":"KA Agu","year":"2013","unstructured":"Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res. 2013;4(2):117\u201324.","journal-title":"Perspect Clin Res"},{"key":"267_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20469047.2015.1122384","volume":"29","author":"K Obebi Cliff-Eribo","year":"2016","unstructured":"Obebi Cliff-Eribo K, Sammons H, Star K, Ralph Edwards I, Osakwe A, Choonara I. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012. Paediatr Int Child Health. 2016;29:1\u20135.","journal-title":"Paediatr Int Child Health"},{"issue":"1","key":"267_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.amjopharm.2006.03.002","volume":"4","author":"JK Nguyen","year":"2006","unstructured":"Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006;4(1):36\u201341.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"2","key":"267_CR30","doi-asserted-by":"publisher","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","volume":"4","author":"EC Davies","year":"2009","unstructured":"Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2):e4439. https:\/\/doi.org\/10.1371\/journal.pone.0004439.","journal-title":"PLoS One"},{"key":"267_CR31","unstructured":"Federal Ministry of Health, Department of Public Health, 2015. 2014 National HIV sero-prevalence sentinel survey among pregnant women attending antenatal clinics in Nigeria. National AIDS\/STI Control Programme."},{"key":"267_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/2325957414557264","volume":"14","author":"R Parkes-Ratanshi","year":"2015","unstructured":"Parkes-Ratanshi R, Katende D, Levin J, Wakeham K, Heiner G, Kamali A, Lalloo DG. Development of severe anemia and changes in hemoglobin in a cohort of HIV-infected Ugandan adults receiving zidovudine, stavudine, and tenofovir containing antiretroviral regimens. J Int Assoc Provid AIDS Care. 2015;14:455\u201362.","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"267_CR33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4314\/gmj.v48i4.5","volume":"48","author":"IA Oreagba","year":"2014","unstructured":"Oreagba IA, Usman S, Olayemi S, Oshikoya K, Opanuga O, Adeyemo T, Lesi O, Dodoo AN, Akanmu A. Pharmacoepidemiology of antiretroviral drugs in a teaching hospital in Lagos, Nigeria. Ghana Med J. 2014;48(4):194\u2013203.","journal-title":"Ghana Med J"},{"issue":"4","key":"267_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/2229-3485.192044","volume":"7","author":"K Prajapati","year":"2016","unstructured":"Prajapati K, Desai M, Shah S, Panchal J, Kapadia J, Dikshit R. An analysis of serious adverse drug reactions at a tertiary care teaching hospital. Perspect Clin Res. 2016;7(4):181\u20136.","journal-title":"Perspect Clin Res"},{"key":"267_CR35","unstructured":"U.S. Department of Health and Human Services. Drugs. Zidovudine. AIDSinfo. https:\/\/aidsinfo.nih.gov\/drugs\/4\/zidovudine\/0\/patient. Accessed 15 Jan 2019."},{"key":"267_CR36","unstructured":"Summary of Product Characteristics. Zidovudine 100\u00a0mg capsule. Aurobindo Pharma\u2014Milpharm Ltd. https:\/\/www.medicines.org.uk\/emc\/product\/4490\/smpc. Accessed 15 Jan 2019."},{"key":"267_CR37","unstructured":"Lamivudine\/zidovudine Mylan 150\u00a0mg\/300\u00a0mg Fil-coated Tablets. Patient Information leaflet. Generics UK T\/A Mylan. https:\/\/www.medicines.org.uk\/emc\/product\/9440\/pil. Accessed 15 Jan 2019."},{"key":"267_CR38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/bjo.77.5.315","volume":"77","author":"SA Geier","year":"1993","unstructured":"Geier SA, Held M, Bogner JR, Kronawitter U, Berninger T, Klauss V, Goebel FD. Impairment of tritan colour vision after initiation of treatment with zidovudine in patients with HIV disease or AIDS. Br J Ophthalmol. 1993;77:315\u20136.","journal-title":"Br J Ophthalmol"},{"key":"267_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.7326\/0003-4819-114-4-297","volume":"114","author":"RG Lalonde","year":"1991","unstructured":"Lalonde RG, Deschenes JG, Seamone C. Zidovudine-induced macular edema. Ann Intern Med. 1991;114:297\u20138.","journal-title":"Ann Intern Med"},{"key":"267_CR40","doi-asserted-by":"crossref","unstructured":"Moodley A, Rae W, Bhigjee A. Visual loss in HIV-associated cryptococcal meningitis: a case series and review of the mechanisms involved. S Afr J HIV Med. 2015;16(1), Art. #305. https:\/\/sajhivmed.org.za\/index.php\/hivmed\/article\/view\/305\/585. Accessed 15 Jan 2019.","DOI":"10.4102\/sajhivmed.v16i1.305"},{"key":"267_CR41","unstructured":"Kestelyn PG, Cunningham ET. HIV\/AIDS and blindness. Bull World Health Organ. 2001;79:208\u201313. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2566369\/pdf\/11285664.pdf. Accessed 15 Jan 2019."},{"key":"267_CR42","unstructured":"Committee on Quality of Health Care in America: Institute of Medicine. To err is human: building a safer health system. National Academy Press, Washington, DC; 2000."},{"issue":"1","key":"267_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","volume":"32","author":"E Lopez-Gonzalez","year":"2009","unstructured":"Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19\u201331.","journal-title":"Drug Saf"},{"issue":"2","key":"267_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.18203\/2320-6012.ijrms20180310","volume":"6","author":"Rohini Gupta","year":"2018","unstructured":"Gupta Rohini, Malhotra Apoorva, Malhotra Pavan. A study on determinants of underreporting of adverse drug reactions among resident doctors. Int J Res Med Sci. 2018;6(2):623\u20137.","journal-title":"Int J Res Med Sci"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-019-00267-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-019-00267-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-019-00267-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:16:26Z","timestamp":1659104186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-019-00267-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,12]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,1]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1007\/s40290-019-00267-2","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,12]]},"assertion":[{"value":"12 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors received no funding for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.K. Ogar declares no conflict of interest relating to this article. A. Abiola declares no conflict of interest relating to this article. D. Yuah declares no conflict of interest relating to this article. A. Ibrahim declares no conflict of interest relating to this article. I.A. Oreagba declares no conflict of interest relating to this article. E.C. Amadi declares no conflict of interest relating to this article. M.C. Adeyeye declares no conflict of interest relating to this article. K.A. Oshikoya declares no conflict of interest relating to this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was not required for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}